KaoYH. 2022. Letter to the Editor: Radioiodine is molecular radiotherapy governed by predictable deterministic radiobiology expressed in gray, not millicuries. Thyroid, 32:340–341.
2.
Simões-PereiraJ, FerreiraTC, LimbertE, CavacoBM, LeiteV. 2021. Outcomes of thyrotropin alfa versus levothyroxine withdrawal-aided radioiodine therapy for distant metastasis of papillary thyroid cancer. Thyroid, 31:1514–1522.
3.
HänscheidH, LassmannM, LusterM, et al.2006. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med, 47:648–654.
4.
HaugenBR, AlexanderEK, BibleKC, et al.2016. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26:1–133.
5.
Klubo-GwiezdzinskaJ, Van NostrandD, AtkinsF, et al.2011. Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. J Clin Endocrinol Metab, 96:3217–3225.
6.
Klubo-GwiezdzinskaJ, BurmanKD, van NostrandD, et al.2012. Radioiodine treatment of metastatic thyroid cancer: Relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid, 22:310–317.
7.
BuffetC, WassermannJ, HechtF, et al.2020. Redifferentiation of radioiodine-refractory thyroid cancers. Endocr Relat Cancer, 27:R113–R132.
